Department of Commerce
Foreign-Trade Zones Board
- [B-90-2026]
Patheon Pharmaceuticals Inc., (Patheon) submitted a notification of proposed production activity to the FTZ Board (the Board) for its facilities in Cincinnati, Ohio within Subzone 46K. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on July 16, 2026.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via www.trade.gov/ftz. The proposed finished product(s) and material(s)/component(s) would be ( printed page 47807) added to the production authority that the Board previously approved for the operation, as reflected on the Board's website.
The proposed finished product is finished vibegron tablets (duty-free).
The proposed foreign-status material is vibegron (active pharmaceutical ingredient is Beta-3 adrenergic receptor) (duty rate 6.5%).
Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is September 8, 2026.
A copy of the notification will be available for public inspection in the “Online FTZ Information System” section of the Board's website.
For further information, contact Christopher Wedderburn at Chris.Wedderburn@trade.gov.
Dated: July 24, 2026.
Elizabeth Whiteman,
Executive Secretary.